Let's take a look at the biotech stocks awaiting FDA decisions in February. Supernus Pharmaceuticals Inc. (SUPN) The FDA decision on Supernus Pharma's SPN-830, an investigational apomorphine infusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback